Achaogen to Present at J.P. Morgan Healthcare Conference
January 03 2018 - 4:01PM
– Company presentation scheduled for January 11,
2018 –
Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical
company developing innovative antibacterials addressing multi-drug
resistant (MDR) gram-negative infections, today announced that the
Company will present at the 36th Annual J.P. Morgan Healthcare
Conference in San Francisco, Calif., on January 11, 2018 at 7:30
a.m. Pacific Time.
A live audio webcast of the presentation will be available in
the "Investors" section of Achaogen’s website, www.achaogen.com. A
replay of the presentation will be archived on the website for 30
days following the conference.
About AchaogenAchaogen is a late-stage
biopharmaceutical company passionately committed to the discovery,
development, and commercialization of innovative antibacterial
treatments for MDR gram-negative infections. Achaogen is developing
plazomicin, its lead product candidate, for the treatment of
serious bacterial infections due to MDR Enterobacteriaceae,
including carbapenem-resistant Enterobacteriaceae. The Food and
Drug Administration has granted plazomicin Breakthrough Therapy
designation for the treatment of bloodstream infections caused by
certain Enterobacteriaceae in patients who have limited or no
alternative treatment options. The Company's second product
candidate is C-Scape, an orally-administered product candidate for
the treatment of serious bacterial infections due to ESBL-producing
Enterobacteriaceae. Achaogen's plazomicin program has been funded,
and its C-Scape program is funded, in part with federal funds from
the Biomedical Advanced Research and Development Authority (BARDA).
Achaogen has other programs in early and late preclinical stages of
development focused on other MDR gram-negative infections and
additional disease areas. All product candidates, including
plazomicin, are investigational only and have not been approved for
commercialization. For more information, please visit
www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor and Media ContactDavid Arrington Vice
President, Investor Relations and Corporate Communications
650.440.5856 darrington@achaogen.com